Aiko Nagayama, PhD | Authors

Articles

Later-Line Management of Metastatic Triple Negative Breast Cancer

November 27, 2019

Triple-negative breast cancer — defined as tumors that lack expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 amplification— is a heterogenous disease and clinically represents a major unmet need in the field of oncology. TNBC is associated with aggressive tumor biology and higher risk of recurrence and visceral metastasis, including brain metastasis.